Recipharm applies for delisting of shares and summons to extraordinary general meeting

The Board of Directors of Recipharm AB (publ) (“Recipharm”) applies for delisting of its B-shares from Nasdaq Stockholm. An extraordinary general meeting to appoint new board members will be held on 10 March 2021.

On 14 December 2020, Roar BidCo AB (“Roar BidCo”) announced a public offer to the shareholders of Recipharm. Roar BidCo today declared the offer unconditional. Roar BidCo controls approximately 95.1 per cent of the total number of shares in Recipharm and has initiated compulsory redemption of the remaining shares.

Based on the information above, and at the request of Roar BidCo, the board of directors of Recipharm has applied for delisting of Recipharm’s B-shares from Nasdaq Stockholm. The last day of trading on Nasdaq Stockholm will be announced as soon as such a date has been decided and communicated to Recipharm by Nasdaq Stockholm.

At the request of Roar BidCo, an extraordinary general meeting in Recipharm will be held on 10 March 2021 in order to appoint new board members of Recipharm. A notice to the extraordinary general meeting will be sent out separately.

Carnegie Investment Bank AB (publ) and Stifel Nicolaus Europe Limited acted as financial advisers and Vinge and Simmons & Simmons as legal advisers to Recipharm in connection with the public offer.


For further information, please contact:
Anders G. Carlberg, chairman of the independent board of Recipharm
By phone: +46 70-543 75 76

The information was submitted for publication, through the agency of the contact person set out above, at 3:30 pm CET on 15 February 2021.

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s annual turnover is approximately SEK 11 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and our services, please visit